2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, CHIP, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Genetic Disorders, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, GVHD, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, CLL, LGL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Research, AML, Translational Research, MDS, MPN, CML, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2516 Haplo-identical peripheral blood stem cell transplantation combined with an unrelated umbilical cord blood might achieve better survival than matched sibling donor transplantation in acute leukemia and myelodysplastic syndrome: A propensity score matching analysis

Sijian Yu, Shengjiao Tang2, Ruijuan Sun, MD3, Zhangkun Li4, Qiong Liu5, Guo Qiu6, Can Liu7, Huan Yang8, Xuan Li, PhD9, Qifa Liu, MD10
1 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
2 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
3 Hebei Yanda Lu Daopei Hospital, Hebei, China
4 Dongguan People's Hospital, Southern Medical University, Dongguan, China
5 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
6 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
7 Hunan Provincial People's Hospital, Changsha, China
8 Department of Hematology, Yueyang Central Hospital, Yueyang, China
9 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
10 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China

Objective: Haploidentical transplantation has expanded donor availability and has been associated with stronger graft-versus-leukemia effects, but whether haploidentical peripheral blood stem cell transplantation augmented with unrelated umbilical cord blood (haplo-PBSC+UCB-SCT) provides superior outcomes to matched sibling donor SCT (MSD-SCT) remains unclear. We compared transplantation outcomes between the two strategies in patients with acute leukemia and myelodysplastic syndrome.

Methods: Eight hundred and twenty-eight patients were enrolled in this retrospective multicenter study. Propensity score matching generated 744 matched patients (372per group). Endpoints included overall survival (OS), disease-free survival (DFS), relapse, non-relapse mortality (NRM), engraftment, and graft-versus-host disease (GVHD).

Results: In the matched cohort, the median age was 38 years old (IQR, 29–50), and 415 (55.8%) patients were male. Diagnoses comprised acute leukemia (AL) in 628 (84.4%) and myelodysplastic syndrome (MDS) in 116 (15.6%) patients. Neutrophil and platelet engraftment were comparable between the two groups. The cumulative incidence of grade II–IV acute GVHD by day 100 was higher after haplo-PBSC+UCB-SCT than that after MSD-SCT (30.4% vs 20.8%; P=0.002), whereas grade III–IV acute GVHD did not differ significantly (9.1% vs 7.0%; P=0.265). At 2 years, chronic GVHD was 29.0% versus 32.0% (P=0.859), and severe chronic GVHD was 4.5% versus 4.1% (P=0.776). Relapse was lower after haplo-PBSC+UCB-SCT (3-year cumulative incidence, 13.4% vs 27.4%; P<0.001), whereas NRM was comparable between groups (P=0.061). With a median follow-up of 29.1 months, haplo-PBSC+UCB-SCT was associated with improved 3-year DFS (74.4% vs 64.3%; P=0.017) and OS (79.8% vs 72.6%; P=0.045). In multivariable Cox regression analysis, haplo-PBSC+UCB-SCT remained independently associated with superior DFS (HR 0.72, 95% CI 0.54–0.95; P = 0.021) and OS (HR 0.72, 95% CI 0.53–0.99; P = 0.040).Subgroup analyses showed improved survival in patients with high-risk disease. 

Conclusion: Compared with MSD-SCT, haplo-PBSC+UCB-SCT was associated with significantly lower risk of relapse and improved survival in patients with AL/MDS, suggesting that it might represent a promising strategy, particularly for those with high-risk disease.
Sijian Yu: No relevant conflicts of interest to declare.